Best Chemotherapy doctors: TOP 128 doctors

Present
Istanbul Florence Nightingale Hospital
Medical Oncology

2022-2024
Memorial Şişli Hospital
Medical Oncology Specialist

2021-2022
Institut Jules Bordet
Clinical Research Fellowship

2020-2022
Marmara University Pendik Training and Research Hospital
Medical Oncology Specialist

2019-2019
Institut Jules Bordet
Clinical Research Fellowship

2016-2019
Marmara University Faculty of Medicine, Department of Medical Oncology
Medical Oncology Fellowship

2014-2016
Golbasi Public Hospital
Internal Medicine Specialist

2013-2014
MD Anderson Cancer Center
Observership

2013
Bellvitge Hospital, Barcelona, Spain
Observership

2009 -2014
Hacettepe University Faculty of Medicine
Internal Medicine Residency

Medical Fields of Interest: 

Chronic Leukemia (Chronic Lymphocytes Leukemia/ Chronic Myeloid Leukemia) 

Chronic Myeloproliferative Diseases (Polistemia Vera, Essential Thrombocytosis, Myelofibrosis etc.) 

Lymphoma (Hodgkin’s and Non-Hodgkin’s) 

Multiple Myeloma 

Education: 

Ege University Faculty of Medicine Medical Doctor 1999 - 2005 

Pamukkale University Specialist in Internal Medicine 2006 - 2011 

Pamukkale University Hematologist 2011 - 2014 

ESCCA Summer School On Cytometry/PRAGUE (May 2014) 

Istanbul Training and Research Hospital Hematology Clinic Associate Professor 2018 

Experience: 

Selçuk University Faculty of Medicine Hospital 2015 

Pamukkale University Internal Medicine Residency Training 2016 - 2011 

Denizli Sarayköy State Hospital 2011 - 2011 

Pamukkale University Hematology Minor Residency Training 2011 - 2014 

Istanbul Training and Research Hospital Hematology Clinic Specialist Doctor 2015 - 2020 

Istanbul Training and Research Hospital Hematology Clinic Responsible Authority 2015 - 2020 

Istanbul Training and Research Hospital Hematology Clinic Responsible Authority/ Lecturer 2019 - 2020 

Istanbul Başakşehir Çam and Şakura City Hospital Hematology Clinic Lecturer 2020 - 2020

Liv Hospital Ulus 2020-

Memberships: 

Turkish Society of Hematology 

The Society of Hematological Education and Research (Member of The Board of Directors

Publications:

32 articles published in international peer-reviewed journals 

12 cases published in international peer-reviewed journals 

11 articles published in national peer-reviewed journals 

5 cases published in national peer-reviewed journals

Pediatric Hematology and Oncology / Pediatric Oncology

Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.

She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.

Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.

Dr. Séverine Iborra is the Chief Physician of the Department of Gynecology and Obstetrics at Städtisches Klinikum Solingen. Her responsibilities include obstetrics, the delivery room, the neonatal unit, and gynecology. The department also includes the Senology/Breast Clinic at the Bergisches Breast Center Solingen, led by Dr. Manuela Seifert.

Dr. Séverine Iborra is originally from France. She began her medical studies at the University of Lyon and later transferred to Albert-Ludwigs University in Freiburg, where she received her medical license in 2007. She earned her doctorate in 2008 for experimental research in molecular oncology. From August 2008 to November 2013, Dr. Iborra worked as a resident at the University Women’s Clinic in Freiburg. After passing her specialist exams in gynecology and obstetrics, she continued her career as a specialist at the same clinic. In November 2015, she moved to RWTH University Hospital Aachen as a senior physician.

At the Clinic for Gynecology and Obstetrics, under the leadership of Prof. Dr. E. Stickeler, Dr. Iborra led the obstetrics department from 2017 to 2019. Since December 2017, she was responsible for organizing education in the department, and in October 2019, she became the Managing Senior Physician and Personnel Senior Physician of the clinic, a position she held until she moved to Solingen.

In addition to her scientific work, with numerous publications and presentations at major gynecological conferences, Dr. Iborra deepened her medical specialties. She obtained certifications in oncological diagnostics and therapy from the Gynecological Oncology Working Group, as well as additional qualifications in Cervical Pathology and Colposcopy (AGCPC), Urogynecology and Pelvic Reconstructive Surgery (AGUP), and the Professional Association of Gynecologists (BVF).

In 2019, Dr. Iborra successfully completed further specialization in “Gynecological Oncology” and “Special Obstetrics and Perinatal Medicine.” She is an active member of leading German medical societies in her field, including the German Society for Gynecology and Obstetrics, the Cervical Pathology and Colposcopy Working Group, and the German Society for Prenatal and Birth Medicine.

Treatments Offered in Our Gynecology Department

• Hysteroscopy and Dilation and Curettage (D&C) for diagnostic and therapeutic purposes.
• Removal of abnormal or symptomatic ovarian findings, such as cysts, while preserving the remaining ovary.
• Oophorectomy (removal of ovaries) in cases of abnormalities or preventively when indicated.
• Myomectomy (removal of uterine fibroids) while preserving the uterus.
• Conservative treatment of fibroids: either medication or embolization performed by radiology specialists.
• Hysterectomy with or without removal of the cervix.
• Diagnosis and clarification of unclear findings in the cervix, vagina, and vulva.
• Dysplasia treatment.
• Endometriosis management.
• Cancer treatment for vulvar, vaginal, cervical, uterine, and ovarian cancers.
• Treatment for incontinence and/or pelvic organ prolapse.

Whenever possible, we offer all procedures as minimally invasive treatments using laparoscopy or the Da Vinci robotic system.

Dr. Murat Ayhan is an Associate Professor of Medical Oncology since 2023. He is an expert in breast, lung, colorectal, gynecological, and urogenital cancers. He focuses on modern cancer treatments such as immunotherapy, smart drugs, targeted therapies, and molecular oncology. Dr. Ayhan provides personalized care based on the latest scientific research.

He is the principal investigator in several global Phase II and III oncology trials. These include studies on GDC-9545, Palbociclib, Atezolizumab, and Apalutamide. Dr. Ayhan has published over 25 articles in international journals. His research covers COVID-19’s effects on cancer patients, drug desensitization, and real-world treatment results.

He is an active member of ESMO and TTOD. Dr. Ayhan has also contributed to oncology reference books on tyrosine kinase inhibitors and oncological emergencies. His work helps advance cancer care for future generations.

Education

• (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
• (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

• (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
• (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye

Dr. Hilmi Apak is a respected pediatric hematology-oncology specialist with more than 21 years of experience. He is trained in pediatric oncology. Dr. Apak has led advanced treatments, including bone marrow transplantation, leukemia chemotherapy, and CAR T-cell therapy.

He has published 75 international medical articles, showing his strong contribution to pediatric oncology research. Dr. Apak has worked as assistant editor for the Turkish Pediatrics Archives Periodical. He has also held important academic and leadership positions, such as Head of Pediatric Hematology-Oncology at Istanbul University-Cerrahpaşa.

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education & Expertise

• 1997 | Hacettepe University Faculty of Medicine – Medical Degree
• 2003 | Uludağ University Faculty of Medicine – Internal Medicine Specialization
• 2007 | Uludağ University Faculty of Medicine – Hematology Subspecialty

Professional Experience

• 1998 (May – September) | Practitioner, Dr. Salaha Health Center, Rize
• 1998 to 2003 | Research Assistant, Uludağ University Faculty of Medicine, Internal Medicine Department
• 2003 to 2007 | Hematology Subspecialist, Uludağ University Faculty of Medicine, Hematology Division
• 2007 to 2011 | Hematology Specialist, Bursa Ali Osman Sönmez Oncology Hospital (Compulsory Service)
• 2011 to 2013 | Hematology Specialist, Private Anadolu Health Center Bone Marrow Transplant Center, Gebze
• 2014 to 2015 | Assistant Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2015 to 2020 | Associate Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2020 to Present | Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine

Courses & Certifications

• Autologous and Allogeneic Stem Cell Transplantation Certificate
• Clinical Phytotherapy Application Certificate
• Flow Cytometry Experience Certificate
• EBMT Stem Cell Transplantation Course

Professional Memberships

• Turkish Medical Chamber
• Turkish Hematology Association (Full Member, No: 893)
• Turkish Therapeutic Apheresis Association (Current President)
• Geriatric Hematology Association
• Hematological Oncology Association
• EBMT (European Bone Marrow Transplantation)

Awards & Recognitions

• 2011 | 6th Turkish Therapeutic Apheresis Congress – Young Researcher Award

Oncologist, specialist in gastrointestinal cancer treatment

Prof. Dr. Ceyhun Bozkurt is a respected Pediatric Hematologist-Oncologist. He is known for his work in childhood blood disorders and cancers. He graduated from Cerrahpaşa Faculty of Medicine. He holds specializations in both Pediatrics and Pediatric Oncology. Since 2019, he has been Professor and Clinical Director at Bahçelievler Medical Park Hospital. He also serves as Vice Director of the Stem Cell Transplant Unit.

Dr. Bozkurt has published over 40 peer-reviewed articles. He is recognized for his work in leukemia, bone marrow transplantation, and stem cell therapy. He is a member of organizations such as SIOP and EBMT. His memberships show his dedication to high standards in clinical care and research.

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Education

• Undergraduate: Istanbul Faculty of Medicine, Istanbul University, 2007
• MSc (Internal Medicine Department): Marmara University Faculty of Medicine, 2012
• PhD (Hematology Clinic): Istanbul Training and Research Hospital, 2018
• Associate Professor (Hematology Clinic): Prof.Dr.Cemil Tascioglu Training and Research Hospital, 2019

Prof. Dr. Rafet Eren graduated from Istanbul Faculty of Medicine in 2007. He completed his Internal Medicine specialty training at Marmara University Faculty of Medicine in 2012. In 2018, he became a Hematology subspecialist at Istanbul Training and Research Hospital. In 2019, he was awarded the title of Associate Professor in the field of Hematology. Afterwards, he worked as a faculty member at Başakşehir Çam and Sakura City Hospital, Bozyaka Training and Research Hospital and Istinye University (Istinye University Bahçeşehir and Liv Hospital Vadistanbul) and is currently working at Biruni University Hospital. Dr. Rafet Eren is a member of Turkish Society of Hematology, Hematology Specialty Society and European Society of Hematology and speaks English fluently. He has around 50 publications in national and international refereed journals.

Scientific Memberships

• Turkish Hematology Association
• Hematology Specialty Society
• Turkish Internal Medicine Specialty Society
• European Society of Hematology
•  

Awards 

• Young Researcher Award (42nd National Hematology Congress), 2016
• Special Jury Paper Award (3rd Hematologic Oncology Congress), 2015
• Paper 3rd Prize (2nd Hematologic Oncology and Bone Marrow Transplantation Symposium), 2016